Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

If approved will become first BCMA targeting drug for myeloma

- PMLiVE

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

- PMLiVE

J&J pushes to expand Imbruvica label after clinical success

Eyes the frontline setting in chronic lymphocytic leukaemia

Life with multiple myeloma – why I’m a lucky man living the dream

Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling...

Blue Latitude Health

- PMLiVE

J&J taps TARIS Biomedical for novel bladder cancer technology

Takes a bigger stake in the bladder cancer market

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

Bristol Myers Squibb logo

BMS’ oral maintenance therapy boosts survival in AML patients

Drug improved survival by almost ten months

- PMLiVE

J&J appeals Oklahoma opioid verdict, claiming ‘errors’ in trial

Cites misuse of public nuisance laws as grounds for appeal

- PMLiVE

J&J splashes $750m on anti-inflammatory drug bermekimab

The drug is currently in phase 2 clinical development

- PMLiVE

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

Both candidates are being studied in multiple myeloma

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links